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Abstract: Systemic sclerosis (SSc) is an autoimmune disease characterized by three main features:
vasculopathy, immune system dysregulation and fibrosis. Long non-coding RNAs (lncRNAs) may
play a role in the pathogenesis of autoimmune diseases and a comprehensive analysis of lncRNAs
expression in SSc is still lacking. We profiled 542,500 transcripts in peripheral blood mononuclear cells
(PBMCs) from 20 SSc patients and 20 healthy donors using Clariom D arrays, confirming the results
by Reverse Transcription Polymerase-chain reaction (RT-PCR). A total of 837 coding-genes were
modulated in SSc patients, whereas only one lncRNA, heterogeneous nuclear ribonucleoprotein U
processed transcript (ncRNA00201), was significantly downregulated. This transcript regulates tumor
proliferation and its gene target hnRNPC (Heterogeneous nuclear ribonucleoproteins C) encodes for
a SSc-associated auto-antigen. NcRNA00201 targeted micro RNAs (miRNAs) regulating the most
highly connected genes in the Protein-Protein interaction (PPI) network of the SSc transcriptome.
A total of 26 of these miRNAs targeted genes involved in pathways connected to the three main
features of SSc and to cancer development including Epidermal growth factor (EGF) receptor, ErbB1
downstream, Sphingosine 1 phosphate receptor 1 (S1P1), Activin receptor-like kinase 1 (ALK1),
Endothelins, Ras homolog family member A (RhoA), Class I Phosphoinositide 3-kinase (PI3K),
mammalian target of rapamycin (mTOR), p38 mitogen-activated protein kinase (MAPK), Ras-related
C3 botulinum toxin substrate 1 (RAC1), Transforming growth factor (TGF)-beta receptor, Myeloid
differentiation primary response 88 (MyD88) and Toll-like receptors (TLRs) pathways. In SSc, the
identification of a unique deregulated lncRNA that regulates genes involved in the three main features
of the disease and in tumor-associated pathways, provides insight in disease pathogenesis and opens
avenues for the design of novel therapeutic strategies.
Keywords: systemic sclerosis; long non-coding RNA; signaling pathway; protein–protein (PPI)
network; gene module
1. Introduction
Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by endothelial disfunction,
dysregulation of the immune system and increased extracellular matrix deposition leading to extended
involvement and fibrosis of skin and internal organs and resulting in a remarkable heterogeneity in
clinical features and in disease course [1].
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Several factors have been shown to contribute to the onset of the disease, such as genetic
susceptibility, environmental factors including viral infections [2,3] and epigenetic mechanisms, such
as microRNAs (miRNAs) [4,5].
We have already reported the gene expression profiling of peripheral blood mononuclear
cells (PBMCs) obtained from patients affected by SSc [6] showing the presence of cancer-related
gene signatures.
Indeed, an increased frequency of different types of cancer, including breast, lung, and
hematologic malignancies in SSc has been already described [7], and has been associated with the
presence of particular autoantibodies [8]. In addition, SSc may also be a paraneoplastic disease [9,10]
suggesting a strong link with cancer.
In this study we focused our attention on the epigenetic mechanisms that may be involved in SSc
pathogenesis by analyzing the expression profiles of long non-coding RNAs (lncRNAs) in SSc patients.
For the first time, we propose an integrated analysis of lncRNAs, miRNAs and gene expression
profiles in SSc patients leading to the identification of lncRNAs modulated in the disease. We identified
a lncRNA involved both in pathogenetically relevant molecular pathways of the disease and in
tumor-associated pathways, strongly associated to the disease.
2. Materials and Methods
2.1. Patients
Twenty patients affected by SSc, attending the Unit of Autoimmune Diseases at the University
Hospital of Verona, Northern Italy, and 20 sex and age matched healthy controls were enrolled.
Both patients and controls were subjects of Caucasian origin from Northern Italy. All patients were
diagnosed accordingly to the American College of Rheumatology (ACR)/European League Against
Rheumatism (Eular) classification criteria for SSc [11]. The distinction between limited (lSSc) and
diffuse cutaneous SSc (dSSc) was performed following the criteria proposed by Le Roy et al. [12]. Ten
patients were affected by lSSc and 10 by dSSc. The clinical and demographic features of the patients
enrolled in the study are reported in Table 1.
Samples obtained from 10 patients with lSSc, 10 patients with dSSc and 20 healthy controls were
used for the gene and lncRNAs expression analysis. Blood samples were collected from patients with
active disease (European Scleroderma Study Group activity index > 3) [13] within 24 months after
diagnosis and in the absence of immunosuppressive therapies. Samples were processed immediately
after the blood draw.
Twenty more patients and 20 healthy controls have been analyzed as validation groups
(Supplementary Table S1).
A written informed consent was obtained by all the participants to the study and the study
protocol was approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrata
di Verona. All the investigations have been performed according to the principles contained in the
Helsinki declaration.
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Table 1. Demographic and clinical and features of patients and healthy subjects enrolled in the study.
Demographic and Clinical Features of Systemic Sclerosis Patients and Healthy Controls
Healthy controls
20
Male/Female 3/17
Mean age (years) 55 ± 11
Patients
lSSc dSSc
10 10
Male/Female 2/8 1/9
Mean age (years) 57 ± 13 55 ± 10
Laboratory findings
ANA 9 (90%) 10 (100%)
Anti-centromere 6 (60%) 2 (20%)
Scl-70 0 8 (80%)
Lung involvement Interstitial disease 3 (30%) 6 (60%)
Pulmonary arterial hypertension 2 (20%) 1 (10%)
Skin involvement
mRSS 8 ± 3 14 ± 8
Digital ulcers 3 (30%) 5 (50%)
Video Capillaroscopy
Early 2 (20%) 3 (30%)
Active 5 (50%) 4 (40%)
Late 3 (30%) 3 (30%)
Kidney involvement 0 (0%) 1 (10%)
Gastro-intestinal
involvement 7 (70%) 9 (90%)
lSSc = limited Systemic Sclerosis; dSSc = diffuse Systemic Sclerosis; ANA = anti-nuclear antibody; Scl-70 = Sclero-70;
mRSS = modified Rodnam Skin Score.
2.2. Microarray Analysis
Blood samples collection was performed using BD (Becton Dickinson)Vacutainer K2EDTA tubes
and 21-gauge needles.
PBMCs were isolated by Ficoll–HyPaque (Pharmacia Biotech, Quebec, Canada) gradient
centrifugation. The PBMCs distribution was similar between patients and controls. Total RNA
extraction from PBMCs (107 cells) was achieved with miRNeasy mini kit (Qiagen GmbH, Hilden,
Germany). cRNA preparation, samples hybridization and scanning were carried out following
the Affymetrix (Affymetrix, Santa Clara, CA, USA) provided protocols, by Cogentech Affymetrix
microarray unit (Campus IFOM IEO, Milan, Italy). All samples were hybridized on Human Clariom
D (Thermo Fisher Scientific, Waltham, MA, USA) gene chip. Signal intensities were analyzed with
the Transcriptome Analysis Console (TAC) 4.0 software (Applied Biosystem, Foster City, CA USA by
Thermo Fisher Scientific).
The Human Clariom D arrays interrogates more than 540,000 human transcripts starting from
as little as 100 pg of total RNA. Signals intensity was background-adjusted, normalized, and
log-transformed using the Signal Space Transformation (SST)-Robust Multi-Array Average algorithm
(RMA).
Differentially expressed genes that showed an expression level at least 1.5 fold different in the
test sample versus control sample at a significant level (p ≤ 0.01) were chosen for final consideration.
p-values were calculated applying the unpaired t-test and Bonferroni multiple testing correction.
Targets annotations of ncRNA00201 were retrieved using starBase v2.0 (http://starbase.sysu.
edu.cn/) where lncRNAs interactions, experimentally validated by high-throughput experimental
technologies, are registered [14].
The list of Gene targets of microRNAs (miRNAs) that are targeted by ncRNA00201 were obtained
from the FunRich database (www.funrich.org/) [15].
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2.3. Protein–Protein Interaction (PPI) Network Construction and Network Clustering
The PPI network was constructed upon the experimentally validated protein–protein interactions
using STRING (Search Tool for the Retrieval of Interacting Genes) version 10.5 (http://string-db.
org/) [16].
Network topological analysis was performed using the Cytoscape software (version 3.4.0) (www.
cytoscape.org) [17].
High-flow areas (highly connected regions) of the network (modules) were detected using the
MCODE plugin of Cytoscape (k-core = 4 and node score cutoff = 0.2).
2.4. Gene Functional Classification and Enrichment Analysis
Functional classification of genes into Biological Processes (BPs) were performed according to the
Gene Ontology (GO) annotations (www.geneontology.org) using Panther expression analysis tools
(version 14.0) (http://pantherdb.org/) [18].
Pathways classification and enrichment (hypergeometric p-value ≤0.05) analysis were performed
with FunRich (version).
2.5. Real Time PCR of ncRNA00201
A total of 500 ng of total RNA was treated with 1 unit of DNase I Amplification Grade (Invitrogen;
Carlsbad, CA, USA.). First-strand cDNA was generated using the SuperScript IV First-Strand Synthesis
System (Invitrogen; Carlsbad, CA, USA.) with random hexamers, according to the manufacturer’s
protocol. Real time PCR was performed in triplicate with PowerUp™ Sybr® Green reagent (Applied
Biosystems; Foster City, CA, USA) in a QuantStudio 6 Flex system (Applied Biosystems; Foster City,
CA, USA). Relative expression levels were calculated for each sample after normalization against the
geometric mean of the housekeeping genes GAPDH and beta-actin (ACTB) expression. The ∆∆Ct
method was used for comparing relative fold expression differences. The data are expressed as fold
changes with respect to healthy. The primers used for the detection were: GCA GGA GAA TCG CTT
GAA C (forward) and ACC CTA CCA TCC AAC TTC AC (reverse).
2.6. Real Time PCR of Genes Modulated in SSc Patients
First-strand cDNA was generated using the SuperScript III First-Strand Synthesis System for
Reverse transcription Polymerase-chain Reaction (RT-PCR) Kit (Invitrogen), with random hexamers,
according to the manufacturer’s protocol. PCR was performed in a total volume of 25 µL containing
1× Taqman Universal PCR Master Mix, no AmpErase UNG and 2.5 µL of cDNA; pre-designed,
Gene-specific primers and probe sets for each gene were obtained from Assay-on-Demande Gene
Expression Products (Applied Biosystems).
Real Time PCR reactions were carried out in a two-tube system and in singleplex. The Real
Time amplifications included 10 min at 95 ◦C (AmpliTaq Gold activation), followed by 40 cycles at
95 ◦C for 15 s and at 60 ◦C for one minute. Thermocycling and signal detection were performed with
7500 Sequence Detector (Applied Biosystems). Signals were detected according to the manufacturer’s
instructions. This technique allows the identification of the cycling point where PCR product is
detectable by means of fluorescence emission (Threshold cycle or Ct value). The Ct value correlates
to the quantity of target mRNA. Relative expression levels were calculated for each sample after
normalization against the housekeeping genes GAPDH, beta-actin and 18s ribosomal RNA (rRNA),
using the ∆∆Ct method for comparing relative fold expression differences. Ct values for each reaction
were determined using TaqMan Software and Digital Store (SDS) analysis software (version 2.4.0). For
each amount of RNA tested triplicate Ct values were averaged. Because Ct values vary linearly with
the logarithm of the amount of RNA, this average represents a geometric mean.
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2.7. Real Time PCR of microRNAs Targeted by ncRNA00201
miRNAs expression was assayed by TaqMan® Advanced miRNA assays chemistry (Applied
Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed and
pre-amplified with TaqMan® Advanced miRNA cDNA synthesis kit following manufacturer’s
instructions (Applied Biosystems, Foster City, CA, USA). Pre-amplified cDNA was diluted 1/10
in nuclease-free water and 5 µL of diluted cDNA for each replicate were loaded in PCR. 20 µL PCR
reactions were composed by 2X Fast Advanced Master Mix and TaqMan® Advanced miRNA assays
for miR-30b-5p, miR-30e-5p, miR-302a-3p, miR-520d-3p, miR-613 and miR-9-5p. The mean of Ct for
hsa-miR-16-5p and hsa-miR-26a-5p expression was used to normalize miRNA expression. Real time
PCR were carried out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems, Foster
City, CA, USA). Expression values were reported as fold change with respect to healthy controls by
∆∆Ct method using QuantStudio Real-Time PCR system software v. 1.3.
2.8. Detection of Soluble Mediators in Sera of SSc Patients
Serum levels of interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF) selectin
P (SELP) chemokine C-X-C motif ligand 10, (CXCL10) and basigin (BSG) were detected using
commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits that were supplied by
Aviva Systems Biology (IL-6; cat. n. OKDB00046), R&D (MIF; cat n. DMF00B and SELP; cat. n.
DPSE00), Life Span Biosciences (LSBio) (CXCL10; cat. n. LS-F586-1) and Creative Diagnostics (BSG; cat
n. DEIA2873).
3. Results
With the aim of identifying lncRNAs potentially involved in SSc pathogenesis, the expression
of more than 540,000 human transcripts, including those ascribed to more than 50,000 lncRNAs
was profiled at the same time, in a cohort of 40 PBMCs samples (20 SSc and 20 healthy subjects).
Transcriptional profiles of SSc patients and healthy subjects were compared and, after a robust
filtering procedure (Bonferroni-corrected p-value ≤ 0.01 and fold change ≥ |1.5|), 837 coding-genes
were significantly modulated (Supplementary Table S2). More than one hundred lncRNAs were
detectable, but only one, long non-coding heterogeneous nuclear ribonucleoprotein U antisense RNA
1 (HNRNPU-AS1, also known as ncRNA00201) satisfied the above mentioned criteria (statistical and
fold change) showing a significant modulation (Table 2).
ncRNA00201 has been showed to be overexpressed in pancreatic ductal adenocarcinoma (PDAC)
tissues and cell lines, and plays a role in the regulation of cell proliferation, invasion, and migration.
Indeed, the knockdown of this lncRNA reduces proliferation and in vitro migration and invasion of
PDAC cell lines [19].
The functional classification by Gene Ontology (http://www.geneontology.org/) of the 837
differentially expressed genes (DEGs) revealed the presence of a large number of differentially
expressed coding genes involved in biological processes (BPs) and signaling pathways that are strictly
connected to SSc pathogenesis, including, immune response BP, interferon alpha/beta signaling, IL-6
mediated signaling events BP, inflammatory response BP, apoptosis BP, angiogenesis BP, Vascular
Endothelial Growth Factor (VEGF) and VEGFR signaling, cell adhesion BP, blood coagulation BP,
endothelin signaling, PDGFR-beta signaling, EGF receptor (ErbB1) signaling, TGF-beta receptor
signaling, extracellular matrix (ECM) component and organization, proteoglycan syndecan mediated
signaling events, and positive regulation of fibroblast proliferation BP.
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Table 2. Selection of significantly differentially expressed genes and lncRNA in Systemic Sclerosis
patients versus healthy subjects.
ID Fold Change p-Value Gene Symbol Description Accession Number
TC0100018570.hg.1 −1.8 0.0003 ncRNA00201 heterogeneous nuclear ribonucleoprotein Uantisense RNA 1 ENST00000366527.3
Apoptosis
TC0100013000.hg.1 1.57 0.0012 CASP9 caspase 9 AB020979.1
TC1000007990.hg.1 2.32 0.0017 DDIT4 DNA damage inducible transcript 4 NM_019058.3
TC1900011729.hg.1 2.1 <0.0001 TIMM50 translocase of inner mitochondrial membrane 50homolog NM_001001563.3
TC0600014045.hg.1 1.65 0.0064 PDCD2 programmed cell death 2 NM_002598.3
TC1800008891.hg.1 2.1 0.0013 BCL2 B-cell CLL/lymphoma 2 NM_000633.2
TC0200010972.hg.1 1.68 0.0003 MFF mitochondrial fission factor NM_001277061.1
TC1500008231.hg.1 1.81 0.0002 AEN apoptosis enhancing nuclease NM_022767.3
TC0500010104.hg.1 1.63 0.0006 DAP death-associated protein NM_001291963.1
Immune Response
TC0300013859.hg.1 2.95 0.0015 CD200 CD200 molecule NM_005944.6
TC2000007519.hg.1 1.59 0.009 CD40 CD40 molecule, TNF receptor superfamilymember 5 NM_001250.5
TC1900008166.hg.1 3.55 0.0029 CD79A CD79a molecule, immunoglobulin-associatedalpha L32754.1
TC1700011430.hg.1 2.61 0.0011 CD79B CD79b molecule, immunoglobulin-associatedbeta KM057839
TC0700009461.hg.1 2.77 0.0008 TRBV24-1 T cell receptor beta variable 24-1 AY373826
TC0600007597.hg.1 1.59 0.0039 LST1 leukocyte specific transcript 1 NM_007161
TC1600011368.hg.1 2 0.0002 LAT linker for activation of T-cells AF036905
TC1400010806.hg.1 6.89 0.0029 IGHV5-51 immunoglobulin heavy variable 5-51 EU433880.1
TC1600007312.hg.1 2.49 <0.0001 IL4R interleukin 4 receptor AF421855.1
Inflammatory Response
TC0400011053.hg.1 9.89 0.0001 CXCL10 chemokine (C-X-C motif) ligand 10 NM_001565.3
TC0400011054.hg.1 2.11 0.0029 CXCL11 chemokine (C-X-C motif) ligand 11 NM_020639.2
TC1100009225.hg.1 2.56 0.0068 CXCR5 chemokine (C-X-C motif) receptor 5 NM_032966.2
TC0900008660.hg.1 1.72 0.0027 PTGS1 prostaglandin-endoperoxide synthase 1 NM_001271367.1
TC0500007231.hg.1 2.42 0.0002 PTGER4 prostaglandin E receptor 4 (subtype EP4) NM_000958.2
TC2200009231.hg.1 1.68 0.0004 MIF macrophage migration inhibitory factor NM_002415.1
TC0300011059.hg.1 2.06 0.0002 GPX1 glutathione peroxidase 1 M21304.1
TC1400007752.hg.1 1.94 0.008 GSTZ1 glutathione S-transferase zeta 1 U86529.1
Cell Adhesion
TC1100012686.hg.1 2.7 0.0015 ESAM endothelial cell adhesion molecule NM_138961.2
TC1100009611.hg.1 4.79 0.0028 JAM3 junctional adhesion molecule 3 AF448478.1
TC1100006494.hg.1 1.86 0.0023 CD151 CD151 molecule (Raph blood group) D29963.1
TC0100016357.hg.1 3.28 0.0008 SELP selectin P NM_003005.3
TC1700011435.hg.1 1.78 0.0002 ICAM2 intercellular adhesion molecule 2 NM_001099788.1
TC1900009625.hg.1 1.54 0.0052 ICAM3 intercellular adhesion molecule 3 NM_002162.4
TC1300009165.hg.1 1.78 0.0025 PCDH9 protocadherin 9 AF169692.2
TC1700012274.hg.1 7.81 0.0006 ITGB3 integrin beta 3 NM_000212.2
Blood Coagulation
TC1100007938.hg.1 2.09 0.0007 FERMT3 fermitin family member 3 XM_017018398.2
TC0600010709.hg.1 3.2 0.0065 F13A1 coagulation factor XIII, A1 polypeptide NM_000129.3
TC0100016828.hg.1 1.55 0.0027 F13B coagulation factor XIII, B polypeptide NM_001994.2
TC0200015194.hg.1 2.29 0.0008 TFPI tissue factor pathway inhibitor NM_006287.5
TC0100008056.hg.1 1.86 0.0063 MPL MPL proto-oncogene, thrombopoietin receptor NM_005373.2
TC2200006614.hg.1 2.88 0.0034 GP1BB glycoprotein Ib (platelet), beta polypeptide NM_000407.4
TC1000008056.hg.1 2.42 0.0031 VCL vinculin M33308.1
TC0700008582.hg.1 1.51 0.0008 SERPINE1 endothelial plasminogen activator inhibitor(PAI-1) NM_000602.4
Angiogenesis
TC0500012519.hg.1 4.74 0.0005 SPARC secreted protein, acidic, cysteine-rich(osteonectin) NM_000602.4
TC0400011053.hg.1 9.89 0.0001 CXCL10 chemokine (C-X-C motif) ligand 10 NM_001565.3
TC1700012468.hg.1 1.74 0.0086 HN1 hematological and neurological expressed 1 AF086910.2
TC1500010429.hg.1 1.91 0.0002 CIB1 calcium and integrin binding 1 (calmyrin) NM_001277764.1
TC1700012274.hg.1 7.81 0.0006 ITGB3 integrin beta 3 NM_000212.2
TC0700009977.hg.1 1.76 0.0014 PDGFA platelet-derived growth factor alpha polypeptide NM_002607.5
TC1900011707.hg.1 1.62 0.0022 GPI glucose-6-phosphate isomerase NM_001184722.1
TC0700011770.hg.1 −1.72 0.0003 KRIT1 KRIT1, ankyrin repeat containing U90268.1
Positive Regulation of Fibroblast Proliferation
TC1200010977.hg.1 1.53 0.0071 CDK4 cyclin-dependent kinase 4 NM_000075.3
TC2200009231.hg.1 1.68 0.0004 MIF macrophage migration inhibitory factor NM_002415.1
TC0800008845.hg.1 2.14 0.0029 MYC v-myc avian myelocytomatosis viral oncogenehomolog NM_002467.5
TC0700009977.hg.1 1.76 0.0014 PDGFA platelet-derived growth factor alpha polypeptide NM_002607.5
TC0100015864.hg.1 1.68 0.0021 S100A6 S100 calcium binding protein A6 NM_014624.3
TC0600007847.hg.1 2.68 0.0032 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) NM_000389
TC0600006873.hg.1 3.9 0.0005 BMP6 bone morphogenetic protein 6 NM_001718.5
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Table 2. Cont.
ID Fold Change p-Value Gene Symbol Description Accession Number
ECM Component and Organization
TC0400012213.hg.1 1.53 0.0072 CTSK cathepsin K NM_001911.2
TC0500012519.hg.1 4.74 0.0005 SPARC secreted protein, acidic, cysteine-rich(osteonectin) J03040.1
TC1900006470.hg.1 1.83 0.0022 BSG basigin (Ok blood group) GU557065.1
TC0300007383.hg.1 1.6 0.0035 DAG1 dystroglycan 1 (dystrophin-associatedglycoprotein 1) L19711.1
TC0600008462.hg.1 3.19 0.0037 COL19A1 collagen, type XIX, alpha 1 NM_001858.5
TC0100010863.hg.1 1.67 0.0087 LAMC1 laminin, gamma 1 (formerly LAMB2) NM_002293.3
TC2000008678.hg.1 2.17 <0.0001 CST3 cystatin C AH002668.2
Interferon Alpha/Beta Signaling
TC1200012708.hg.1 2.66 0.0007 OAS1 2-5-oligoadenylate synthetase 1 AY730627.1
TC0100015921.hg.1 1.92 <0.0001 ADAR adenosine deaminase, RNA-specific NM_015841.4
TC1400010584.hg.1 1.57 0.0015 IRF9 interferon regulatory factor 9 NM_006084.4
TC1500008232.hg.1 2.04 0.0002 ISG20 interferon stimulated exonuclease gene 20kDa NM_002201.5
TC0100013445.hg.1 3.3 0.0018 IFI6 interferon, alpha-inducible protein 6 NM_002038.3
TC1700007931.hg.1 1.52 0.0078 IFI35 interferon-induced protein 35 NM_001330230.1
TC1000008396.hg.1 6.08 0.0059 IFIT2 interferon-induced protein with tetratricopeptiderepeats 2 NM_001547.4
TC1000008401.hg.1 1.65 0.0037 IFIT5 interferon-induced protein with tetratricopeptiderepeats 5 NM_012420.2
IL6-Mediated Signaling Events
TC1300008688.hg.1 1.65 0.0072 FOXO1 forkhead box O1 NM_002015.3
TC0700006890.hg.1 12.69 0.0044 IL6 interleukin 6 NM_000600.4
TC1700011903.hg.1 2.03 0.0027 SOCS3 suppressor of cytokine signaling 3 NM_003955.4
TC0800008845.hg.1 2.14 0.0029 MYC v-myc avian myelocytomatosis viral oncogenehomolog NM_002467.5
TGF-Beta Receptor Signaling
TC0100017258.hg.1 1.75 0.0003 BATF3 basic leucine zipper transcription factor, ATF-like3 NM_018664.2
TC1800008891.hg.1 2.1 0.0013 BCL2 B-cell CLL/lymphoma 2 NM_000633.2
TC0500013301.hg.1 2.69 0.0015 DAB2 Dab, mitogen-responsive phosphoprotein,homolog 2 NM_001244871.1
TC1300008688.hg.1 1.65 0.0072 FOXO1 forkhead box O1 NM_002015.3
TC1400009426.hg.1 1.85 0.0001 MAX MYC associated factor X NM_002382.4
TC0500011418.hg.1 1.55 0.0053 MEF2C myocyte enhancer factor 2C NM_002397.4
TC0600013126.hg.1 2.56 0.0005 PTPRK protein tyrosine phosphatase, receptor type, K NM_001291983.1
TC0100011533.hg.1 1.93 0.0076 ATF3 activating transcription factor 3 AY426987.1
PDGFR-Beta Signaling Pathway
TC1000007990.hg.1 2.32 0.0017 DDIT4 DNA damage inducible transcript 4 NM_019058.3
TC0300009916.hg.1 1.68 0.0009 HES1 hes family bHLH transcription factor 1 Y07572.1
TC1900010009.hg.1 1.81 0.0021 JUND jun D proto-oncogene X56681.1
TC0200008742.hg.1 2.26 0.0001 NCK2 NCK adaptor protein 2 NM_003581.4
TC1500010757.hg.1 1.89 0.0082 RAB11A RAB11A, member RAS oncogene family AF000231.1
TC0300008735.hg.1 1.65 0.0014 RAB7A RAB7A, member RAS oncogene family NM_004637.5
TC0900010543.hg.1 1.8 0.0034 TLE1 transducin-like enhancer of split 1 (E(sp1)homolog M99435.1
TC1000008056.hg.1 2.42 0.0031 VCL vinculin M33308.1
VEGF and VEGFR Signaling Network
TC0300011899.hg.1 −1.55 0.0038 CBLB Cbl proto-oncogene B, E3 ubiquitin protein ligase NM_001321786.1
TC0600011809.hg.1 1.9 <0.0001 CCND3 cyclin D3 NM_001136017.3
TC1200010977.hg.1 1.53 0.0071 CDK4 cyclin-dependent kinase 4 NM_000075.3
TC0500012938.hg.1 2.09 <0.0001 CLTB clathrin, light chain B M20470.1
TC0300011059.hg.1 2.06 0.0002 GPX1 glutathione peroxidase 1 M21304.1
TC0200014790.hg.1 1.95 0.0009 GRB14 growth factor receptor bound protein 14 L76687.1
TC0900012167.hg.1 1.81 0.0005 GSN gelsolin NM_000177.4
TC0100014014.hg.1 1.53 0.0022 PRDX1 peroxiredoxin 1 NM_002574.3
Proteoglycan Syndecan-Mediated Signaling Events
TC0600006873.hg.1 3.9 0.0005 BMP6 bone morphogenetic protein 6 NM_001718.5
TC1900006470.hg.1 1.83 0.0022 BSG basigin (Ok blood group) D45131.1
TC0300007055.hg.1 4.54 0.0005 CTDSPL CTD small phosphatase like NM_001008392.1
TC0200014790.hg.1 1.95 0.0009 GRB14 growth factor receptor bound protein 14 L76687.1
TC0200008742.hg.1 2.26 0.0001 NCK2 NCK adaptor protein 2 AF047487.1
TC1100013140.hg.1 1.86 <0.0001 TAF10 TATA-box binding protein associated factor 10 NM_006284.3
TC0500007912.hg.1 −1.58 0.005 ZFYVE16 zinc finger, FYVE domain containing 16 BC030808.1
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Table 2. Cont.
ID Fold Change p-Value Gene Symbol Description Accession Number
Endothelins Signaling Pathway
TC1000007990.hg.1 2.32 0.0017 DDIT4 DNA damage inducible transcript 4 NM_019058.3
TC1900009991.hg.1 1.78 0.0055 JAK3 Janus kinase 3 NM_000215.3
TC0300007432.hg.1 1.84 0.0029 MAPKAPK3 mitogen-activated protein kinase-activatedprotein kinase 3 NM_001243926.1
TC2200008477.hg.1 1.79 0.0044 PATZ1 POZ (BTB) and AT hook containing zinc finger 1 NM_174907.3
TC0600013126.hg.1 2.56 0.0005 PTPRK protein tyrosine phosphatase, receptor type, K NM_001135648.2
TC0100016357.hg.1 3.28 0.0008 SELP selectin P (granule membrane protein 140kDa,antigen CD62) NM_003005.3
TC1000008056.hg.1 2.42 0.0031 VCL vinculin M33308.1
EGF Receptor (ErbB1) Signaling Pathway
TC0300011899.hg.1 −1.55 0.0038 CBLB Cbl proto-oncogene B, E3 ubiquitin protein ligase NM_001321786.1
TC1200010977.hg.1 1.53 0.0071 CDK4 cyclin-dependent kinase 4 NM_000075.3
TC0600011635.hg.1 1.87 0.0098 FKBP5 FK506 binding protein 5 NM_004117.3
TC0300007410.hg.1 1.56 0.0005 GNAI2 G protein, alpha inhibiting activity polypeptide 2 NM_002070.3
TC0100010863.hg.1 1.67 0.0087 LAMC1 laminin, gamma 1 (formerly LAMB2) NM_002293.3
TC0200007446.hg.1 1.67 0.0003 PRKCE protein kinase C, epsilon NM_005400.2
TC0700008582.hg.1 1.51 0.0008 SERPINE1 serpin peptidase inhibitor, clade E, member 1 NM_000602.4
TC1800006937.hg.1 1.99 0.0013 TAF4B TATA box binding protein (TBP)-associatedfactor, 105kDa NM_001293725.1
Table 2 shows a selection of DEGs involved in these meaningful biological processes
and pathways.
The modulation of genes involved in immune response highlighted the immune system alterations
that characterize SSc and other autoimmune diseases. Not surprising, in SSc samples we found
upregulation of genes belonging to the type alpha and beta interferon signaling pathways, that is
a common trait of autoimmune diseases and, this finding has also been previously overserved in
SSc PBMCs [20]. In addition, we found a strong upregulation of interleukin-6 (IL-6) (F.C. 12.69) a
cytokine involved in inflammatory and autoimmune diseases including SSc and, besides that, we
found overexpression of several members of its signaling pathway (see Table 2).
The presence of modulated genes involved in the inflammatory process reflected the chronic
inflammation that accompanies SSc. Moreover the upregulation of genes involved in apoptosis is
not surprising, since apoptosis is the first event of vascular damage in early SSc [2]. The modulation
of genes involved in angiogenesis gives evidence of the angiogenic response to tissue ischemia and
vascular damage that occurs in the initial stages of SSc. We also have to mention that, members of the
proangiogenetic VEGF and VEGFR signaling pathway were modulated in SSc (see Table 2).
The vascular response to endothelial damage consists of endothelial activation with increased
expression of adhesion molecules and, indeed, several adhesion molecules were overexpressed in
SSc samples.
As it is well known, the spectrum of vascular abnormalities that characterizes SSc also involves
disorders of the blood coagulation-fibrinolysis system [21] and, noteworthy, we found upregulation of
several genes involved in blood coagulation.
The earliest vascular changes in SSc also include a dysregulated control of vascular tone and
indeed we have to mention that endothelins are among the strongest vasoconstrictors known, and are
involved in vascular diseases of several organs. Interestingly in SSc samples several components of the
endothelins pathway were overexpressed.
Moreover, we found modulation of members of the platelet derived growth factor receptor-beta
(PDGFR-B). PDGFR-B has been implicated in SSc [22] and it plays a role in activation of the epidermal
growth factor receptor (EGFR) that is also involved in the disease. In particular, in scleroderma
fibroblasts, aberrant activation of EGF-mediated signaling pathways, can upregulate the receptor
II of transforming growth factor beta (TGFBRII) [23], the growth factor primary playing a role in
the development of connective tissue fibrosis that is typically involved in SSc pathogenesis and,
noteworthy, members of the EGFR pathway were modulated in SSc. Moreover the deregulation of
both PDGF and EGF pathways has been already described in a previous study on gene expression
profiles in SSc peripheral blood [24].
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Consistently with these findings, other modulated genes were involved in the signaling of the
profibrotic cytokine TGF-beta.
Fibrosis is supported by extracellular matrix (ECM) remodeling and, consistently, we found
overexpression of ECM components and of molecules involved in ECM organization. Moreover, we
found an increased expression of molecules involved in proteoglycan syndecan-mediated signaling
events (see Table 2) and of genes involved in the positive regulation of fibroblasts proliferation.
The expression levels of ncRNA00201, selected miRNAs and coding genes were validated by
RT-PCR in the entire series of the analyzed patients and in an expanded panel of SSc patients (20) and
healthy controls (20 subjects) (Supplementary Table S1). Significantly different expression levels were
found for all tested transcripts as compared to healthy controls (Supplementary Figures S1 and S2).
Gene expression results were also confirmed by the detection of several soluble mediators
(including interleukin-6, IL-6; macrophage migration inhibitory factor, MIF; selectin P, SELP; chemokine
C-X-C motif ligand 10, CXCL10 and basigin, BSG) in the sera of SSc patients. As shown in
Supplementary Figure S3 the serum levels of all the tested molecules were significantly different
in SSc patients when compared to healthy donors.
Noteworthy, the pathways enrichment analysis confirmed that the important signaling networks
described in Table 2 were all included in the list of pathways significantly (p < 0.05) enriched in
the 837 genes, along with others that were likewise connected to autoimmune and inflammatory
response, vascular damage (i.e., apoptosis, platelet activation and aggregation, Urokinase-type
plasminogen activator (uPA) and uPAR-mediated, Thrombin/protease-activated receptor (PAR)
signaling etc.) and fibrosis (i.e., glypican, syndecan-3 mediated, regulation of nuclear Small Mother
Against Decapentaplegic (SMAD) 2/3 signaling etc.) (Supplementary Table S3).
Since modulated genes were well representative of the main features of the disease, we decided
to verify if the only modulated lncRNA could be functionally connected to SSc transcriptome, thus
playing a role in SSc pathogenesis. To this purpose we extracted the complete list of experimentally
validated genes and microRNAs (miRNAs) targets of ncRNA00201, and we found that 56 miRNAs
and 31 genes were annotated as target of ncRNA00201 (Supplementary Table S4). One of the gene
targets, named hnRNPC, belonged to a subfamily of ubiquitously expressed heterogeneous nuclear
ribonucleoproteins (hnRNPs) and interestingly encoded for a known antigen identified in SSc [25].
To dissect all the possible connections between ncRNA00201 and the SSc transcriptome we
analyzed the lists of genes targeted by each of the 56 miRNAs (3759 genes) selecting only transcripts
that also resulted significantly modulated on the array. Among the 3759 gene targets, 138 were
modulated in SSc patients and were further analyzed along with their targeting miRNAs (47/56)
(Supplementary Table S5). We therefore selected only those miRNAs that targeted genes with evidence
of modulation in SSc patients to bona fide outline authentic interactions that are most probably
established in SSc.
The analysis of signaling pathways, in which the 138 DEGs may be involved, showed that these
genes were present in the 83% (147/176) of pathways significantly enriched in the SSc transcriptome
(Supplementary Table S6).
A protein–protein interaction (PPI) network including all the protein products of the 837
modulated genes that showed experimentally validated interactions was constructed and, the obtained
network included 693 nodes (interacting partners) and 2226 edges (interactions), showing a good PPI
enrichment p-value (<10−16) indicating that the network contained significantly more interactions
than expected. In other words, the connected proteins had more interactions among themselves than
what would be expected for a random set of proteins of similar size, drawn from the genome. Such an
enrichment indicates that these proteins are biologically connected, as a group.
The topological analysis of the PPI network showed the presence of a large number of targeted
genes in areas with high density of connections (Figure 1).
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Figure 1. Degree Sorted Circle Layout of the Protein–Protein Interaction (PPI) network of differentially
expressed genes in Systemic Sclerosis patients. Nodes are ordered around a circle based on their degree
of connectivity (number of edges). Genes not targeted, genes targeted but not included in modules and
genes targeted and included in the modules are differently colored.
When a modular analysis was performed, we could identify six areas of the PPI network in which
the most highly connected genes were present (modules).
Since the modulation of highly connected genes is expected to have a wider impact on the
transcriptome than the targeting of several isolated genes, we checked if ncRNA00201 could target
genes included in the modules and, noteworthy, we observed that genes modulated by miRNA targets
of ncRNA00201 were present in each of the 6 modules (Supplementary Table S7).
To dissect the most relevant interactions through which ncRNA00201 could influence the
pathogenesis of the disease, the miRNAs targeted by ncRNA00201 were filtered, prioritizing those that
targeted at least 7 genes in the whole SSc transcriptome (i.e., the 837 modulated genes) and at least
two modules. By these criteria, 26 miRNAs target of ncRNA00201 were selected. Table 3 shows the 26
selected miRNAs and summarizes their targeted genes in the SSc transcriptome and in the modules.
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Table 3. Selected miRNAs targeted by ncRNA00201.
Total Genes Targeted in
Systemic Sclerosis Disease References Genes Targeted in Modules (M)
hsa-miR-30e-5p
22 breast, lung and other cancers [26] M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-206
20 lung cancer [27] M2 (CXCL11) M5 (GCH1)
hsa-miR-30b-5p
20 systemic sclerosis; breast, lung and othercancers [26,28] M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-30c-5p
20 breast, lung and other cancers [26] M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-9-5p
20 squamous cell carcinoma [29] M2 (CXCL11) M5 (GCH1)
hsa-miR-30a-5p
19 breast and other cancers [26] M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-30d-5p
19 breast and other cancers [26] M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-613
19 breast cancer [30] M2 (CXCL11) M5 (GCH1)
hsa-miR-302c-3p
17 breast cancer [31] M1 (SOCS3, IRF9) M5 (GUCY1A3)
hsa-miR-302e
13 lung cancer [32] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-372-3p
12 squamous cell carcinoma [33] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302a-3p
11 breast cancer [31] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302b-3p
11 breast cancer [31] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302d-3p
11 breast cancer [31] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-31-5p
11 systemic sclerosis and breast cancer [34,35] M3 (KDELR2) M5 (PAX5, SPARC, GCH1)
hsa-miR-520a-3p
11 breast cancer [36] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520b
11 breast, ovarian and other cancers [37,38] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520c-3p
11 breast cancer [39] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520d-3p
11 breast cancer [40] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520e
11 breast cancer [41] M1 (IRF9) M5 (GUCY1A3)
hsa-miR-181d-5p
10 leukemia, colon cancer, glioblastoma [42–44] M1 (CBLB) M5 (PAX5, BCL2) M4 (AP1S3)
hsa-miR-181a-5p
8 leukemia, breast cancer, neuroblastoma [42,45,46] M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-181b-5p
8 leukemia, lung cancer, neuroblastoma [42,46,47] M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-181c-5p
8 leukemia, sarcoma [42,48] M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-211-5p
7 renal cell carcinoma, melanoma, carcinoma,breast cancer [49–51] M5 (SPARC, BCL2) M6 (PSME1)
hsa-miR-204-5p
7 lung and breast cancer, leukemia,carcinoma [52,53] M5 (SPARC, BCL2) M6 (PSME1)
Interestingly, among the selected miRNAs, miR-30b-5p and miR-31-5p were previously described
as deregulated in SSc whereas, all the 26 miRNAs are modulated in several types of human cancer
(Table 3).
The selected miRNAs targeted module-associated-genes with important biological significance,
indeed these genes were involved in inflammation, in the modulation of immune response regulating
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signaling, in maintaining vascular homeostasis, in tissue remodeling, and also in metastasis
development in many cancers.
Indeed, Module 1 (M1) was targeted by 20 miRNAs (see Table 3) that globally modulated SOCS3,
UBE2F, UBE2J1, IRF9, and CBLB. SOCS3, a major regulator of inflammation, is rapidly induced
by JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling during the
inflammatory response. UBE2F and UBE2J1 are ubiquitin conjugating enzymes that are involved in
inflammation and in metastasis development in many cancers [54]. IRF9 is strongly induced by type I
interferons and CBLB is involved in the regulation of immune response modulating signaling by both
T-cell and B-cell receptors [55].
M2 was targeted by eight miRNAs including the members of the miRNA 30s family (miR-30a,
30b, 30c, 30d, and 30d-5p miRNAs) that targeted GNAI2 and miR-206, miR-9-5p and miR-613 that
modulated CXCL11. GNAI2 plays a role in chemokine receptor signaling in B-cells [56] and CXCL11 is
a proinflammatory molecule whose serum levels are increased in SSc [57].
M3 was targeted by miR-31-5p that modulated KDELR2. This molecule is involved in extracellular
matrix degradation and in the signaling of the Src family proteins that is activated during cell invasion
leading to metastasis development [58].
In M4 the gene APIS3 was targeted by members of the miR-181s family (including
miR-181-a/b/c/d-5p). Lacking of AP1S3 gene has been associated to the development of skin
inflammation [59] and interestingly, AP1S3 was down-modulated in SSc samples (see Supplementary
Table S1).
M5 was the most targeted module since it was targeted by 21 out of the 26 selected miRNAs
(see Table 3). In this module 5 genes were targeted including GCH1, GUCY1A3, PAX5, SPARC and
BCL2. GCH1, also named GTPCH1 is implicated in the synthesis of the three nitric oxide synthases
(NOS1–3) [60] and endothelial cell GCH1-dependent endothelial nitric oxide (eNOS) regulation plays
an important role in maintaining vascular homeostasis [61]. GUCY1A3 encodes for the α1 subunit of
nitric oxide (NO) receptor and is involved in the control of smooth muscle cells relaxation [62].
PAX5 is indispensable for the B-cell lineage specification and maintenance [63] and has been
implicated in human B cell malignancies, including acute lymphoblastic leukemias and non-Hodgkin
lymphomas [64].
SPARC (also known as osteonectin) is a glycoprotein of the extracellular matrix expressed in
concomitance with tissue remodeling and wound repair. Interestingly SPARC upregulation has been
described in cultured dermal fibroblasts from patients with SSc [65] and it has been observed that
SPARC silencing can reduce collagens overproduction in SSc skin fibroblasts [66].
The BCL2 gene is involved in apoptosis and its co-expression with the oncogene MYC is associated
with a poor prognosis in B-cell lymphoma patients [67]. Interestingly both BCL2 and MYC were
upregulated in SSc patients (see Supplementary Table S1).
In module M6, PSME1 was targeted by miR-204-5p and miR-211-5p. PSME1, also named
PA28, is a proteasome component that influences antigen processing. Proteasomal system plays
crucial roles in important biological processes including cell differentiation, proliferation, apoptosis,
transcriptional activation and angiogenesis, and is a pivotal target for treatment of several diseases
including autoimmune diseases and cancer [68].
We also observed that a large proportion of the pathways enriched (p < 0.05) in modulated genes
targeted by the 26 selected miRNAs were linked to the three main features of the disease (i.e., immune
and inflammatory response, vasculitis and fibrosis) thus confirming their possible involvement in
SSc pathogenesis. Figure 2 shows a selection of the above mentioned enriched signaling pathways in
which are involved modulated genes targeted by 11 of the 26 selected miRNAs.
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Figure 2. Schematic representation of enriched (p < 0.05) signaling pathways modulated by selected
micro s (miRNAs) that are targeted by non-coding RNA 201 (ncRNA00201). Pathways are grouped
by their relevance to the disease features including immune and inflammatory response, vasculitis
and fibrosis.
Interestingly, several of the aforementioned pathways are also deregulated in many
forms of cancer. These pathways included for example EGF receptor, ErbB1 downstream,
Sphingosine-1-phosphate receptor 1 (S1P1), Arf6 downstream, ALK1, Endothelins, RhoA, Class I
PI3K (Phosphatidylinositol 3-kinase), mTOR, p38 MAPK, RAC1, TGF-beta receptor, MyD88 and
Toll-like receptors signaling pathways (Figure 3).
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that were targeted by the highest number of selected miRNAs (see Table 2).
Interestingly, we observed that they were associated to a large number of pathways (136) and that
82 (60%) of such pathways are significantly enriched (p < 0.05) in the whole SSc transcriptome such as
for example interferon alpha/beta, apoptosis, endothelins, PDGF receptor beta, TGF-beta receptor and
regulation of SMAD (Supplementary Table S8).
4. Discussion
Though it has been widely recognized that lncRNAs play a pivotal role in the regulation of
autoimmune diseases [69], an extensive analysis of lncRNAs in SSc is still lacking. We therefore
performed a comprehensive analysis assessing the expression profiles of a very large number of
lncRNAs in SSc patients, and we could find that, differently from what we had already observed in
other autoimmune diseases [70], a single lncRNA, namely ncRNA00201, appeared to be significantly
modulated in SSc.
Among the gene targets of ncRNA00201, there is the hnRNPC, which encodes for a known
autoantigen in SSc [25].
Interestingly, ncRNA00201 has been showed to be involved in cancer proliferation [19] and this
finding may reinforce the hypothesis of a link between SSc and tumor development, as we have
recently suggested [6].
By a combined analysis of he expression profiles of a vast number of coding and non-coding
transcripts, we have been able to obs rve that ncRNA00201 alone controls biological processes and
pathway closely relate to the three main features of SSc, including immune and inflammatory
response, vasculitis and fibrosis.
We moreover identified 26 miRNAs by which ncRNA00201 could modulate the expression
of several genes crucial to the disease, thus highlighting the most effective lncRNA-miRNA-gene
interactions in SSc. Interestingly, all the 26 miRNAs are modulated in several types of human cancer.
We also showed that ncRNA00201 is able to modulate pathways that are associated to both SSc
and tumor development such as EGF receptor, ErbB1 downstream, S1P1, Arf6 downstream, ALK1,
Endothelins, RhoA, Class I PI3K, mTOR, p38 MAPK, RAC1, TGF-beta receptor, MyD88 and Toll-like
receptors signaling pathways, confirming our previous observations [6].
Indeed, changes in EGFR expression and autoantibodies to this receptor have been observed in
patients with SSc [71], nevertheless there is evidence for the involvement of EGFR signaling in the
development of different carcinoma types [72].
The activation of S1P signaling pathway can induce many of the alterations observed in SSc
patients [73], moreover, S1P receptors regulate cell proliferation in various tumors [74].
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Arf6 is involved in angiogenesis [75] and is implicated in tumor metastasis [76]. ALK1 inhibition
reduces pro-fibrotic genes expression in SSc fibroblasts [77] moreover, this gene is an emerging target
for antiangiogenic therapy in cancer [78]. Endothelins (ET) play important roles in the in the fibrotic
process associated to SSc and have a documented role in the development of cancer [79]. RhoA
signaling, is frequently altered in many types of human tumors [80] and the expression of RhoA is
elevated in SSc endothelial cells [81].
PI3K signaling is involved in collagen gene expression and in the antiapoptotic phenotype that
characterizes SSc fibroblasts [82,83]. This pathway acts in synergy with the mTOR signaling in the
development of many cancers [84]. Interestingly, mTOR blockade can reduce the pro-fibrotic action of
TGF-beta and its therapeutic implications for SSc have been suggested [85].
The p38 MAPK and the Rac1 signaling were also associated to SSc fibrosis [86,87] and to cancer
progression [88,89].
Finally, other signaling typically involved in both SSc and cancer development are TGF-beta
receptor and MyD88/Toll-like receptors pathways [90–93].
In conclusion, this study is the first report of a unique lncRNA that controls gene networks that
may contribute to SSc pathogenesis and that may play a predisposing role to the well documented
development of malignancies in SSc.
Finally, we may propose that ncRNA00201 may be a potential target in the development of novel
therapeutic strategies.
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